Prevalence and incidence of chronic kidney disease stage G5 in Japan

被引:0
|
作者
Kunihiro Yamagata
Takashi Yagisawa
Shigeru Nakai
Masaaki Nakayama
Enyu Imai
Motoshi Hattori
Kunitoshi Iseki
Takashi Akiba
机构
[1] University of Tsukuba,Department of Nephrology, Faculty of Medicine
[2] Jichi Medical University,Department of Renal Surgery
[3] Fujita Health Medical University,Department of Nephrology and Hypertension
[4] Fukushima Medical University School of Medicine,Department of Pediatric Nephrology
[5] Imai Nakayama Temple Clinic,Dialysis Unit
[6] School of Medicine,Department of Blood Purification, Kidney Center
[7] Tokyo Women’s Medical University,undefined
[8] University Hospital of the Ryukyus,undefined
[9] Tokyo Women’s Medical University,undefined
来源
关键词
Chronic kidney disease; End-stage kidney disease; Renal replacement therapy;
D O I
暂无
中图分类号
学科分类号
摘要
The prevalence and incidence of end-stage kidney disease (ESKD) have continued to increase worldwide. Japan was known as having the highest prevalence of ESKD in the world; however, Taiwan took this place in 2001, with the USA still in third position. However, the prevalence data from Japan and Taiwan consisted of dialysis patients only. The prevalence and incidence of Kidney Transplantation (KT) in Japan were quite low, and the number of KT patients among those with ESKD was regarded as negligibly small. However, the number of KT recipients has increased recently. Furthermore, there are no reports about nationwide surveys on the prevalence and incidence of predialysis chronic kidney failure patients in Japan. This review describes our recent study on the estimated number of chronic kidney disease (CKD) stage G5 patients and the number of ESKD patients living in Japan, obtained via the cooperation of five related medical societies. From the results, as of Dec 31, 2007, 275,242 patients had received dialysis therapy and 10,013 patients had a functional transplanted kidney, and as of Dec 31, 2008, 286,406 patients had received dialysis therapy and 11,157 patients had a functional transplanted kidney. Consequently, there were 285,255 patients with CKD who reached ESKD and were living in Japan in 2008 and 297,563 in 2009. We also estimated that there were 67,000 predialysis CKD stage G5 patients in 2009, 37,365 patients introduced to dialysis therapy, and 101 patients who received pre-emptive renal transplantation in this year. In total, there were 37,466 patients who newly required renal replacement therapy (RRT) in 2009. Not only the average ages, but also the primary renal diseases of the new ESKD patients in each RRT modality were different.
引用
收藏
页码:54 / 64
页数:10
相关论文
共 50 条
  • [1] Prevalence and incidence of chronic kidney disease stage G5 in Japan
    Yamagata, Kunihiro
    Yagisawa, Takashi
    Nakai, Shigeru
    Nakayama, Masaaki
    Imai, Enyu
    Hattori, Motoshi
    Iseki, Kunitoshi
    Akiba, Takashi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2015, 19 (01) : 54 - 64
  • [2] Inpatient educational program delays the need for dialysis in patients with chronic kidney disease stage G5
    Takagi, Wei Han
    Osako, Kiyomi
    Machida, Shinji
    Koitabashi, Kenichiro
    Shibagaki, Yugo
    Sakurada, Tsutomu
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (02) : 166 - 172
  • [3] Inpatient educational program delays the need for dialysis in patients with chronic kidney disease stage G5
    Wei Han Takagi
    Kiyomi Osako
    Shinji Machida
    Kenichiro Koitabashi
    Yugo Shibagaki
    Tsutomu Sakurada
    Clinical and Experimental Nephrology, 2021, 25 : 166 - 172
  • [4] Prevalence and incidence of chronic kidney disease stage 3–5 – results from KidDiCo
    Jan Dominik Kampmann
    James Goya Heaf
    Christian Backer Mogensen
    Hans Mickley
    Donna Lykke Wolff
    Frans Brandt
    BMC Nephrology, 24
  • [5] EFFECT OF TOLVAPTAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE G5 AND IMPACT OF CONCOMITANT USE OF THIAZIDE DIURETICS
    Uchiyama, Kiyotaka
    Kojima, Daiki
    Hama, Eriko Yoshida
    Nagasaka, Tomoki
    Nakayama, Takashin
    Takahashi, Rina
    Tajima, Takaya
    Morimoto, Kohkichi
    Washida, Naoki
    Itoh, Hiroshi
    JOURNAL OF HYPERTENSION, 2023, 41 : E386 - E386
  • [6] Gap acidosis except lactic acidosis develops and progresses during chronic kidney disease stage G5
    Tanemoto, Masayuki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2019, 23 (08) : 1045 - 1049
  • [7] Hyperchloremic acidosis develops at the stage G4 and shifts to high anion gap acidosis at the stage G5 in chronic kidney disease
    Tanemoto, Masayuki
    Kamachi, Ryohei
    Kimura, Takahide
    Yamada, Seiki
    Yokoyama, Takeshi
    Okazaki, Yukio
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (12) : 1140 - 1143
  • [8] Gap acidosis except lactic acidosis develops and progresses during chronic kidney disease stage G5
    Masayuki Tanemoto
    Clinical and Experimental Nephrology, 2019, 23 : 1045 - 1049
  • [9] Hyperchloremic acidosis develops at the stage G4 and shifts to high anion gap acidosis at the stage G5 in chronic kidney disease
    Masayuki Tanemoto
    Ryohei Kamachi
    Takahide Kimura
    Seiki Yamada
    Takeshi Yokoyama
    Yukio Okazaki
    Clinical and Experimental Nephrology, 2020, 24 : 1140 - 1143
  • [10] Prevalence and incidence of chronic kidney disease stage 3-5-results from KidDiCo
    Kampmann, Jan Dominik
    Heaf, James Goya
    Mogensen, Christian Backer
    Mickley, Hans
    Wolff, Donna Lykke
    Brandt, Frans
    BMC NEPHROLOGY, 2023, 24 (01)